Brief: Santhera Says It Received Approval For Agamree® (Vamorolone) As A Treatment For Duchenne Muscular Dystrophy In The UK

Santhera Pharmaceuticals Holding AG

12/01/2024 06:02

Jan 12 (Reuters) - Santhera Pharmaceuticals Holding AG
 SANN.S :
    * SANTHERA RECEIVES APPROVAL FOR AGAMREE® (VAMOROLONE) AS A
TREATMENT FOR DUCHENNE MUSCULAR DYSTROPHY IN THE UNITED KINGDOM
    * LAUNCHES OF AGAMREE IN EUROPE, WITH GERMANY TAKING LEAD,
ARE
PLANNED TO START IN Q1-2024

Source text for Eikon:  ID:nGNX95zLGc 
Further company coverage:  SANN.S 

 ((Reuters.Briefs@thomsonreuters.com;))